Nurix Therapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines. Its 8-K reports furnish quarterly and annual financial results, corporate presentations, clinical-program updates for bexobrutideg and pipeline programs, and other material events tied to research, development and financing activity.
The company’s SEC disclosures also cover its common stock listed on the Nasdaq Global Market, shelf registration and at-the-market equity distribution arrangements, underwritten equity offerings, and use-of-proceeds language tied to clinical development and research programs. Proxy and governance filings document board composition, director appointments, compensation programs, committee assignments and annual stockholder meeting matters.
NRIX notice of proposed sale of Common Stock restricted units. The filing lists 5,394 Restricted Stock Units authorized for sale with an effective date of 04/30/2026. It also reports 3,214 Common shares sold during the prior three months on 04/30/2026.
Nurix Therapeutics reported updated Phase 1a/1b clinical data for its oral BTK degrader bexobrutideg (NX-5948) in patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. The drug was generally well tolerated across 142 treated patients, including 86 at the 600 mg once-daily recommended Phase 2 dose, with no dose-limiting toxicities and no treatment-related Grade 5 adverse events.
In the Phase 1a cohort of 48 heavily pretreated patients, the objective response rate was 83.0% among 47 evaluable patients, with a median progression-free survival of 22.1 months and responses seen in high-risk subgroups. Earlier-line Phase 1b cohorts showed objective response rates of 92.9% in BTK inhibitor–treated, BCL2 inhibitor–naïve patients and 84.2% in BTK inhibitor–naïve and treatment-naïve patients, with most patients remaining on treatment at the data cutoff.
Nurix Therapeutics entered a global license and collaboration agreement with Roche for bexobrutideg (NX-5948), an investigational oral BTK degrader for cancers and immune diseases. Roche will pay Nurix a $700 million upfront and up to $2.3 billion in potential development, regulatory, and sales milestones.
The partners will co-develop and co-commercialize bexobrutideg in the U.S., sharing development costs 40% Nurix and 60% Roche and splitting U.S. profits and losses 50/50. Outside the U.S., Roche will lead commercialization while Nurix receives tiered royalties from the low teens to the high teens. The deal becomes effective after required antitrust clearances.
Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring reported an open-market sale and an option exercise involving the company’s common stock. She sold 8,148 shares of common stock at a weighted average price of $16.5995 per share under a pre-arranged Rule 10b5-1 trading plan, with sale prices ranging from $16.35 to $17.10. In a related move, she exercised employee stock options covering 3,422 shares at an exercise price of $1.86 per share, converting them into common stock. Following these transactions, she directly holds 13,579 shares of common stock and 5,221 employee stock options.
Christine Ring submitted a Form 144 notice relating to sales of Common Stock. The filing lists multiple 10b5-1 sales executed in April–May 2026, with individual transactions such as 05/04/2026: 3,368 shares ($57,118.25) and 05/01/2026: 5,394 shares ($90,406.68).
The filing also lists securities acquired earlier by means of Restricted Stock Units (678 shares, 05/02/2022), an Employee Stock Purchase Plan (4,048 shares, 08/11/2020), and previously exercised options (3,422 shares, 10/01/2019), each shown with its grant/acquisition date.
Nurix Therapeutics director Paul M. Silva received a new stock option grant covering 31,250 shares of Common Stock. The option has an exercise price of $15.86 per share and expires on May 14, 2036.
The option vests in full on the earlier of the company’s next annual stockholder meeting or May 15, 2027, in each case only if Silva continues providing service to the company through the vesting date. Following this grant, he holds stock options for 31,250 shares directly.
Nurix Therapeutics director Edward C. Saltzman received a stock option grant for 31,250 shares of common stock. The option has an exercise price of $15.86 per share and expires on May 14, 2036. All 31,250 underlying shares are reported as held directly after this award.
The option vests in full on the earlier of the company’s next annual stockholder meeting or May 15, 2027, assuming Mr. Saltzman continues to provide service to Nurix through the vesting date. This is a compensation-related grant, not an open-market share purchase or sale.
Nurix Therapeutics, Inc. director Judith A. Reinsdorf received a grant of stock options covering 31,250 shares of common stock. The options have an exercise price of $15.86 per share and expire on May 14, 2036. The entire award vests 100% on the earlier of the company’s next annual stockholder meeting or May 15, 2027, subject to her continued service, giving her 31,250 options beneficially owned after this grant.
Nurix Therapeutics director David L. Lacey received a grant of stock options covering 31,250 shares of common stock. The options have an exercise price of $15.86 per share and are held directly. Following this award, he holds options on 31,250 shares.
The option grant vests in full on the earlier of the company’s next annual stockholder meeting or May 15, 2027, in each case only if he continues providing service to Nurix on that vesting date. The options expire on May 14, 2036 if not exercised.
Nurix Therapeutics director Anil Kapur received a stock option grant covering 31,250 shares of common stock. The option has an exercise price of $15.86 per share and expires on May 14, 2036. This is a compensation-related award, not an open-market purchase.
The option vests 100% on the earlier of the company’s next annual stockholder meeting or May 15, 2027, as long as Kapur continues providing service to Nurix through the vesting date. After this grant, his directly held option position from this award totals 31,250 underlying shares.